GU Cancers Symposium 2014 - Effect of prior abiraterone or enzalutamide on sipuleucel-T manufacture in PROCEED patients - Poster

SAN FRANCISCO, CA USA ( - Presented by Nicholas J. Vogelzang, Jeffrey L. Vacirca, Philip W. Kantoff, Mark Creamer Scholz, Shaker R. Dakhil, Luke T. Nordquist, Celestia S. Higano, A. Oliver Sartor, Matthew R. Cooperberg, Andrew Sandler, Candice McCoy, James Boyd Whitmore, Robert Claude Tyler, and Andrew J. Armstrong at the 2014 Genitourinary Cancers Symposium - January 30 - February 1, 2014 - San Francisco Marriott Marquis - San Francisco, California USA

gucancer 2014 Vogelzang Sip-T thumb


Comprehensive Cancer Centers of Nevada, Las Vegas, NV; National Translational Research Group, East Setauket, NY; Dana-Farber Cancer Institute/Harvard Medical School, Boston, MA; Prostate Oncology Specialists, Marina del Rey, CA; Cancer Center of Kansas, Wichita, KS; Urology Cancer Center & GU Research Network, Omaha, NE; University of Washington/Seattle Cancer Care Alliance, Seattle, WA; Tulane University School of Medicine, New Orleans, LA; University of California, San Francisco, San Francisco, CA; Dendreon Corporation, Seattle, WA; Duke University, Durham, NC